CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avanir Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avanir Pharmaceuticals Inc
20 Enterprise Ste 200
Phone: (949) 389-6700p:949 389-6700 ALISO VIEJO, CA  92656-7104  United States Ticker: AVNRAVNR

This company was Merged or Acquired on 1/13/2015.
This company ceased filing statements with the SEC on 1/15/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20149/30/2014YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Craig A.Wheeler 53 5/1/2007 1/1/2005
President, Chief Executive Officer, Director Keith A.Katkin 42 3/1/2007 7/1/2005
Principal Financial Officer, Vice President - Finance Christine G.Ocampo 41 1/1/2010 3/1/2007
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Avanir Acquisition Corp.
Avanir Holding Company
AVNR

General Information
Number of Employees: 484 (As of 9/30/2014)
Outstanding Shares: 193,758,703 (As of 12/1/2014)
Shareholders: 24,581
Stock Exchange: NASD
Federal Tax Id: 330314804
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023